Previous 10 | Next 10 |
Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Specifically, the Tumor Treating Fields product (TTFields) pioneer's stock was down by a hefty 7.36% on heavy volume...
Novocure Limited (NVCR) Q4 2022 Results Earnings Conference Call February 23, 2023, 08:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - C...
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2022 Earnings Call Feb 23, 2023 , 8:00 a.m. ET Ingrid Goldberg Continue reading For further details see: NovoCure (NVCR) Q4 2022 Earnings Call Transcript
The following slide deck was published by NovoCure Limited in conjunction with their 2022 Q4 earnings call. For further details see: NovoCure Limited 2022 Q4 - Results - Earnings Call Presentation
NovoCure press release ( NASDAQ: NVCR ): Q4 GAAP EPS of -$0.36 misses by $0.07 . Revenue of $128.43M (-3.6% Y/Y) beats by $1.23M . The United States, EMEA and Japan contributed $98.6 million, $17.0 million, and $7.9 million in quarterly net revenues, resp...
Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. ...
Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study...
NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $127.2M (-4.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward rev...
In the biotech world, investors often heave a sigh of relief when an important clinical goal is met. That was the case Wednesday with oncology specialist Novocure (NASDAQ: NVCR) , which enjoyed an almost 2% rise in its share price on the day, beating the S&P 500 index's 0.3% gain....
Final data from the PANOVA-3 study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...